Logan Brooks

Sunesis (United States) — United States

Mathematics · Physical Sciences

18h-index2.3kcitations36works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

COVID-19 epidemiological studies(18), Data-Driven Disease Surveillance(17), Influenza Virus Research Studies(12), Computational Drug Discovery Methods(5), Climate variability and models(3)

Publications33 total

Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations
CPT Pharmacometrics & Systems Pharmacology·2025Open Access
Evaluation of FluSight influenza forecasting in the 2021–22 and 2022–23 seasons with a new target laboratory-confirmed influenza hospitalizations
UNC Libraries·2024Open Access
Quantitative Pharmacology for Dose and Regimen Determination of Cevostamab Monotherapy in Relapsed/Refractory Multiple Myeloma
Blood·2024
Pharmacokinetics (PK) of the anti-ST2 monoclonal antibody, astegolimab
2024· 2 cited
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma
Cancers·2024Open Access
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma
2024Open Access
Evaluation of FluSight influenza forecasting in the 2021–22 and 2022–23 seasons with a new target laboratory-confirmed influenza hospitalizations
Nature Communications·2024· 46 citedOpen Access
From Noise to Signal: Unveiling Treatment Effects from Digital Health Data through Pharmacology-Informed Neural-SDE
arXiv (Cornell University)·2024Open Access
Bridging the Gap: A Comprehensive Checklist for Hybrid Pharmacometrics-Machine Learning Model Building to Support Oncology Clinical Development
2024Open Access
Evaluation of FluSight influenza forecasting in the 2021-22 and 2022-23 seasons with a new target laboratory-confirmed influenza hospitalizations
2023· 6 citedOpen Access
epidatr: Client for Delphi's 'Epidata' API
2023· 1 citedOpen Access
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results
Ophthalmology·2023· 38 citedOpen Access
Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*
Critical Care Medicine·2022· 19 citedOpen Access
Comparing trained and untrained probabilistic ensemble forecasts of COVID-19 cases and deaths in the United States
International Journal of Forecasting·2022· 64 citedOpen Access
Comparing trained and untrained probabilistic ensemble forecasts of COVID-19 cases and deaths in the United States
arXiv (Cornell University)·2022· 3 citedOpen Access
A Phase 1 study of <scp>GDC</scp>‐0134, a dual leucine zipper kinase inhibitor, in <scp>ALS</scp>
Annals of Clinical and Translational Neurology·2022· 36 citedOpen Access
An open repository of real-time COVID-19 indicators
Proceedings of the National Academy of Sciences·2021· 65 citedOpen Access
An Open Repository of Real-Time COVID-19 Indicators
2021· 10 citedOpen Access
Client for Delphi's 'COVIDcast Epidata' API [R package covidcast version 0.4.2]
2021
covidcast: Client for Delphi's 'COVIDcast Epidata' API
2021· 5 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Roni Rosenfeld(15), Ryan J. Tibshirani(15), Nicholas G Reich(11), Evan L Ray(11), Jeffrey Shaman(10), David Farrow(10), Sasikiran Kandula(9), Matthew Biggerstaff(9), Michael A. Johansson(9), Teresa K. Yamana(8), Sangwon Hyun(8), Craig McGowan(6), Jacob Bien(6), Dmitry Shemetov(6), Spencer J. Fox(5), Alessandro Vespignani(5), Alden Green(5), Addison J. Hu(5), Daniel J. McDonald(5), Nikos I Bosse(5)